Supplementary Figures S1-6 from Pharmacological and Structural Characterizations of Naquotinib, a Novel Third-Generation EGFR Tyrosine Kinase Inhibitor, in &lt;i&gt;EGFR&lt;/i&gt;-Mutated Non–Small Cell Lung Cancer